A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer

scientific article published on 01 November 2010

A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3816/CLC.2010.N.101
P953full work available at URLhttps://api.elsevier.com/content/article/PII:S1525730411700444?httpAccept=text/plain
https://api.elsevier.com/content/article/PII:S1525730411700444?httpAccept=text/xml
P698PubMed publication ID21071331

P2093author name stringFrank Beier
Charles Butts
Glenwood Goss
Denis Soulières
Andrew Maksymiuk
Kevin Jasas
Peter M. Ellis
Guy Ely
R. Nevin Murray
Colum J. Smith
P2860cites workConsolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504Q44438556
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. OncologyQ46253129
Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 SQ46641106
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.Q46672565
Heterogeneity of mucin gene expression in normal and neoplastic tissuesQ53482902
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ?pure? ductal carcinoma in situ of the breastQ57892833
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapyQ71254387
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancerQ73181790
Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancerQ79345729
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003Q80345591
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinomaQ80654652
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancerQ81231679
Cancer statistics, 2009Q29547625
Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).Q33299169
Estimates of the cancer incidence and mortality in Europe in 2006.Q34575047
Mucins: structure, function, and associations with malignancyQ35284163
Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathwaysQ36752265
L-BLP25: a peptide vaccine strategy in non small cell lung cancerQ36899928
Immune-potentiating effects of the chemotherapeutic drug cyclophosphamideQ37186715
Strategies used for MUC1 immunotherapy: preclinical studiesQ37259594
Immunotherapy for lung cancerQ37435397
Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell lineQ38345618
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectlung cancerQ47912
P304page(s)391-395
P577publication date2010-11-01
P1433published inClinical Lung CancerQ332299
P1476titleA multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer
A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer
P478volume11

Reverse relations

cites work (P2860)
Q40342047Active-specific immunotherapy for non-small cell lung cancer
Q34494018Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response
Q36088986Canertinib induces ototoxicity in three preclinical models
Q58804834Combining immunotherapy with radiation therapy in thoracic oncology
Q34269196EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.
Q34044082INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
Q90053061Immunomodulatory Nanosystems
Q38022807Immunotherapies for non-small-cell lung cancer and mesothelioma.
Q52624364Immunotherapy in surgically resectable non-small cell lung cancer.
Q37698684Influence of human immune cells on cancer: studies at the University of Colorado
Q34430511L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review
Q34418761Liposomes as vaccine delivery systems: a review of the recent advances
Q38091088MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge
Q35886589Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study
Q58740200New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
Q26997993Particle-mediated delivery of cytokines for immunotherapy
Q44991597Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Q35886761Tecemotide: an antigen-specific cancer immunotherapy
Q46720677Translational nanoparticle engineering for cancer vaccines.
Q84534783Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
Q36207901Why has active immunotherapy not worked in lung cancer?
Q54380709[Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].

Search more.